Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ueg2.12717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review.
United European Gastroenterol J
December 2024
Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
The heterogeneity and suboptimal efficacy of biological treatments and small molecule drugs necessitate their precise selection based on biomarkers that predict therapeutic responses in inflammatory bowel disease. Recent studies have identified numerous novel biomarkers predictive of responses to biologics and small molecule modulators, utilizing a variety of omics approaches in inflammatory bowel disease. In this review, we systematically examine baseline omics biomarkers that predict responses to biological therapies and small molecule drugs, drawing on literature from PubMed.
View Article and Find Full Text PDFImpact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease.
Rev Esp Enferm Dig
December 2024
Hospital Pharmacy, Hospital Universitario Reina Sofía, España.
Background: Understanding the relationship between ustekinumab (UST) exposure and clinical outcomes in inflammatory bowel disease (IBD) induction is crucial. However, evidence remains limited, highlighting the need to comprehend UST's pharmacokinetic variability for tailored treatments.
Aims: This study aimed to investigate the association between UST exposure during the induction phase and clinical outcomes and identifying factors associated with UST exposure during this period.
The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?
United European Gastroenterol J
November 2024
IBD Unit, Gastroenterology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Considerations in Paediatric and Adolescent Inflammatory Bowel Disease.
J Crohns Colitis
October 2024
Department of Paediatric Gastroenterology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
The incidence of inflammatory bowel disease [IBD] is rising most rapidly among children and adolescents. Paediatric-onset IBD is associated with a more extensive and severe disease course compared to adult-onset IBD. At a young age, screening for underlying genetic and immunological disorders is important and may impact treatment management.
View Article and Find Full Text PDFEfficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks.
Br J Dermatol
October 2024
Amgen Inc., Thousand Oaks, CA, USA.
Article Synopsis
- ABP 654 is a biosimilar to ustekinumab, sharing identical amino acid sequences and similar safety and pharmacokinetics in healthy individuals.
- A clinical study was conducted to compare the efficacy and safety of ABP 654 versus ustekinumab in patients with moderate-to-severe plaque psoriasis, focusing on improvements in psoriasis severity.
- Results showed no significant difference in efficacy (PASI improvement) between ABP 654 and ustekinumab, and both treatments exhibited similar safety and immunogenicity profiles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!